{"url_path":"/sec/nus/10-k/2026/item-15","section_key":"item-15","section_title":"Item 15 EXHIBITS AND FINANCIAL STATEMENT SCHEDULES","topic":"sec","document":{"doc_type":"10-K","doc_date":"2026-02-13","source_url":"https://www.sec.gov/Archives/edgar/data/1021561/0001140361-26-005130-index.html","accession_number":"0001140361-26-005130","cik":"0001021561","ticker":"NUS","issuer_name":"NU SKIN ENTERPRISES, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1021561/0001140361-26-005130-index.html","primary_entity_key":"0001021561","primary_entity_name":"NU SKIN ENTERPRISES, INC."},"word_count":1281,"has_tables":true,"body_markdown":"ITEM 15.\n\nEXHIBITS AND FINANCIAL STATEMENT SCHEDULES\n\nDocuments filed as part of this Form 10-K:\n\n1.\n\nFinancial Statements. See Index to Consolidated Financial Statements under Item 8 of Part II.\n\n2.\n\nFinancial Statement Schedules. N/A\n\n3.\n\nExhibits. References to the “Company” shall mean Nu Skin Enterprises, Inc. Unless otherwise noted, the SEC file number for exhibits incorporated by reference is 001-12421.\n\n2.1\n\n[Unit Purchase Agreement, dated as of January 2, 2025, by and among Mavely Seller LLC, Mavely LLC, Clout.io\nHoldings, Inc. and Mavrck LLC (incorporated by reference to Exhibit 2.1 to the Company’s Current Report on Form 8-K filed January 3, 2025).](https://www.sec.gov/Archives/edgar/data/1021561/000114036125000113/ef20041017_ex2-1.htm)\n\n \n\n \n\n3.1\n\n[Amended and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 to the\nCompany’s Registration Statement on Form S-1 filed September 16, 1996, file no. 333-12073).](https://www.sec.gov/Archives/edgar/data/1021561/0000950109-96-005995.txt)\n\n \n\n \n\n3.2\n\n[Certificate of Amendment to the Amended and Restated Certificate of Incorporation (incorporated by reference to\nExhibit 3.2 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2009, filed March 1, 2010).](https://www.sec.gov/Archives/edgar/data/1021561/000102156110000024/ex3-2.htm)\n\n \n\n \n\n3.3\n\n[Certificate of Designation, Preferences and Relative Participating, Optional and Other Special Rights of Preferred\nStock and Qualifications, Limitations and Restrictions Thereof (incorporated by reference to Exhibit 3.3 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2004, filed March 15, 2005).](https://www.sec.gov/Archives/edgar/data/1021561/000103393205000011/ex3-3.htm)\n\n \n\n \n\n3.4\n\n[Sixth Amended and Restated Bylaws of Nu Skin Enterprises, Inc. (incorporated by reference to Exhibit 3.1\nto the Company’s Current Report on Form 8-K filed November 1, 2024).](https://www.sec.gov/Archives/edgar/data/1021561/000114036124045001/ef20037801_ex3-1.htm)\n\n \n\n \n\n4.1\n\n[Specimen Form of Stock Certificate for Class A Common Stock (incorporated by reference to Exhibit 4.1 to\nthe Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed February 16, 2023).](https://www.sec.gov/Archives/edgar/data/1021561/000114036123007348/brhc10046901_ex4-1.htm)\n\n \n\n \n\n4.2\n\n[Description of the Registrant’s Securities Registered Under Section 12 of the Securities Exchange Act of\n1934 (incorporated by reference to Exhibit 4.2 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed February 15, 2024).](https://www.sec.gov/Archives/edgar/data/1021561/000114036124008111/ef20015265_ex4-2.htm)\n\n \n\n \n\n10.1\n\n[Amended and Restated Credit Agreement among the Company, various financial institutions, and Bank of\nAmerica, N.A. as administrative agent, dated as of June 14, 2022 (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed June 17, 2022).](https://www.sec.gov/Archives/edgar/data/1021561/000114036122023342/brhc10038831_ex10-1.htm)\n\n \n\n \n\n#10.2\n\n[Second Amended and Restated Nu Skin Enterprises, Inc. 2010 Omnibus Incentive Plan (“Second Amended and Restated 2010\nPlan”) (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed May 24, 2016).](https://www.sec.gov/Archives/edgar/data/1021561/000102156116000134/ex10-1.htm)\n\n \n\n \n\n#10.3\n\n[Form of Second Amended and Restated 2010 Plan Performance Stock Option Grant Agreement (incorporated by\nreference to Exhibit 10.13 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed February 13, 2020).](https://www.sec.gov/Archives/edgar/data/1021561/000114036120002997/exhibit10_13.htm)\n\n \n\n \n\n#10.4\n\n[Third Amended and Restated 2010 Omnibus Incentive Plan (“Third Amended and Restated 2010 Plan”) (incorporated by\nreference to Exhibit 99.1 to the Company’s Registration Statement on Form S-8 filed June 3, 2020, file no. 333-238908).](https://www.sec.gov/Archives/edgar/data/1021561/000114036120012979/ex99_1.htm)\n\n104\n\n[Table of Contents](#TABLEOFCONTENTS)\n\n#10.5\n\n[Form of Third Amended and Restated 2010 Plan Restricted Stock Unit Grant Agreement (incorporated by\nreference to Exhibit 10.5 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed February 15, 2024).](https://www.sec.gov/Archives/edgar/data/1021561/000114036124008111/ef20015265_ex10-5.htm)\n\n \n\n \n\n#10.6\n\n[Form of Third Amended and Restated 2010 Plan Performance Restricted Stock Unit Grant Agreement\n(incorporated by reference to Exhibit 10.6 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed February 15, 2024).](https://www.sec.gov/Archives/edgar/data/1021561/000114036124008111/ef20015265_ex10-6.htm)\n\n \n\n \n\n#10.7\n\n[Form of Third Amended and Restated 2010 Plan Performance Stock Option Grant Agreement (incorporated by\nreference to Exhibit 10.14 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed February 11, 2021).](https://www.sec.gov/Archives/edgar/data/1021561/000114036121004212/brhc10019752_ex10-14.htm)\n\n \n\n \n\n#10.8\n\n[2024 Omnibus Incentive Plan (“2024 Plan”) (incorporated by reference to Exhibit 10.1 to the Company’s\nCurrent Report on Form 8-K filed June 6, 2024).](https://www.sec.gov/Archives/edgar/data/1021561/000114036124029122/ef20030699_ex10-1.htm)\n\n \n\n \n\n#10.9\n\n[Form of 2024 Plan Restricted Stock Unit Grant Agreement (incorporated by reference to Exhibit 10.9 to the\nCompany’s Annual Report on Form 10-K for the year ended December 31, 2024, filed February 14, 2025).](https://www.sec.gov/Archives/edgar/data/1021561/000114036125004907/ef20039018_ex10-9.htm)\n\n \n\n \n\n#10.10\n\n[Form of 2024 Plan Performance Restricted Stock Unit Grant Agreement (incorporated by reference to\nExhibit 10.10 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed February 14, 2025).](https://www.sec.gov/Archives/edgar/data/1021561/000114036125004907/ef20039018_ex10-10.htm)\n\n \n\n \n\n#10.11\n\n[Amended and Restated 2024 Omnibus Incentive Plan (“Amended and Restated 2024 Plan”) (incorporated by\nreference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed May 30, 2025).](https://www.sec.gov/Archives/edgar/data/1021561/000114036125020939/ef20049959_ex10-1.htm)\n\n \n\n \n\n#10.12\n\n[Form of Amended and Restated 2024 Plan Director Restricted Stock Unit Grant Agreement (incorporated by\nreference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2025, filed August 8, 2025).](https://www.sec.gov/Archives/edgar/data/1021561/000114036125029673/ef20050377_ex10-2.htm)\n\n \n\n \n\n#10.13\n\n[Nu Skin Enterprises, Inc. Amended and Restated 2009 Key Employee Death Benefit Plan (incorporated by\nreference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023, filed August 2, 2023).](https://www.sec.gov/Archives/edgar/data/1021561/000114036123037437/brhc20056518_ex10-1.htm)\n\n \n\n \n\n#10.14\n\n[Fourth Amended and Restated Nu Skin Enterprises, Inc. Deferred Compensation Plan, effective as of\nJanuary 1, 2022 (incorporated by reference to Exhibit 10.18 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed February 16, 2022).](https://www.sec.gov/Archives/edgar/data/1021561/000114036122005656/brhc10033829_ex10-18.htm)\n\n \n\n \n\n#10.15\n\n[Amendment 1 to Fourth Amended and Restated Nu Skin Enterprises, Inc. Deferred Compensation Plan\n(incorporated by reference to Exhibit 10.2 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023, filed August 2, 2023).](https://www.sec.gov/Archives/edgar/data/1021561/000114036123037437/brhc20056518_ex10-2.htm)\n\n \n\n \n\n#10.16\n\n[Form of Indemnification Agreement between the Company and its Executive Officers and Directors (incorporated by\nreference to Exhibit 10.1 to the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2016, filed November 4, 2016).](https://www.sec.gov/Archives/edgar/data/1021561/000102156116000188/ex10-1.htm)\n\n \n\n \n\n#10.17\n\n[Nu Skin Enterprises, Inc. Executive Severance Policy, amended and restated effective as of January 4,\n2023 (incorporated by reference to Exhibit 10.16 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, filed February 14, 2025).](https://www.sec.gov/Archives/edgar/data/1021561/000114036125004907/ef20039018_ex10-16.htm)\n\n \n\n \n\n19.1\n\n[Nu Skin Enterprises, Inc. Securities Trading Policy (incorporated by reference to Exhibit 19.1 to the\nCompany’s Annual Report on Form 10-K for the year ended December 31, 2024, filed February 14, 2025).](https://www.sec.gov/Archives/edgar/data/1021561/000114036125004907/ef20039018_ex19-1.htm)\n\n105\n\n[Table of Contents](#TABLEOFCONTENTS)\n\n[*21.1](ef20060638_ex21-1.htm)\n\nSubsidiaries of the Company.\n\n \n\n \n\n[*23.1](ef20060638_ex23-1.htm)\n\nConsent of PricewaterhouseCoopers LLP.\n\n \n\n \n\n[*31.1](ef20060638_ex31-1.htm)\n\nCertification by Ryan S. Napierski, Chief Executive Officer, pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.\n\n \n\n \n\n[*31.2](ef20060638_ex31-2.htm)\n\nCertification by James D. Thomas, Chief Financial Officer, pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.\n\n \n\n \n\n[*32.1](ef20060638_ex32-1.htm)\n\nCertification by Ryan S. Napierski, Chief Executive Officer, pursuant to Section 1350, Chapter 63 of Title 18, United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.\n\n \n\n \n\n[*32.2](ef20060638_ex32-2.htm)\n\nCertification by James D. Thomas, Chief Financial Officer, pursuant to Section 1350, Chapter 63 of Title 18, United States Code, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.\n\n \n\n \n\n97.1\n\n[Nu Skin Enterprises, Inc. Executive Officer Incentive Compensation Recovery Policy (incorporated by\nreference to Exhibit 97.1 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed February 15, 2024).](https://www.sec.gov/Archives/edgar/data/1021561/000114036124008111/ef20015265_ex97-1.htm)\n\n \n\n \n\n*101.INS\n\nInline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document).\n\n \n\n \n\n*101.SCH\n\nInline XBRL Taxonomy Extension Schema Document.\n\n \n\n \n\n*101.CAL\n\nInline XBRL Taxonomy Extension Calculation Linkbase Document.\n\n \n\n \n\n*101.DEF\n\nInline XBRL Taxonomy Extension Definition Linkbase Document.\n\n \n\n \n\n*101.LAB\n\nInline XBRL Taxonomy Extension Label Linkbase Document.\n\n \n\n \n\n*101.PRE\n\nInline XBRL Taxonomy Extension Presentation Linkbase Document.\n\n \n\n \n\n*104\n\nCover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).\n\n*\n\nFiled or furnished herewith.\n\n#\n\nManagement contract or compensatory plan or arrangement."}